Insulin as a Biomarker to Predict Vascular Protection From Weight-Loss Therapy∗  by Anderson, Todd J.
Journal of the American College of Cardiology Vol. 62, No. 24, 2013
 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.08.716EDITORIAL COMMENT
Insulin as a Biomarker to
Predict Vascular Protection
From Weight-Loss Therapy*
Todd J. Anderson, MD
Calgary, Alberta, Canada
The vascular endothelium has long been recognized as a key
modulator of the detrimental effects of cardiovascular risk
factors. Through the release of vasoactive substances, including
nitric oxide (NO), a healthy endothelium is cardioprotective.
In response to perturbations imposed by enhanced oxidative
stress, endothelial dysfunction is associated with atheroscle-
rosis and its consequences. Conduit vessel endothelial function
is most commonly measured by assessing ﬂow-mediated
dilation (FMD) of the brachial artery. More recently, there
has been interest in assessing microvascular function by eval-
uating the stimulus for FMD, namely hyperemic ﬂow (1).
These indexes have been shown to be independent predictors
of cardiovascular events (2). Hence, they are accepted athe-
rosclerotic surrogates to evaluate the impact of risk factors and
their treatment in clinical research studies.
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Obesity has emerged over the past 2 decades as a major
global healthcare epidemic (3). It has been recognized
as a cardiovascular risk factor through the metabolic conse-
quences of visceral abdominal fat. Adipokines, free fatty
acids, inﬂammatory mediators, and hyperinsulinemia
contribute to vascular risk and lead to endothelial dysfunc-
tion. Insulin is an NO-mediated vasodilator that also
releases endothelin 1; thus, it has complex effects on blood
vessel function. Insulin-resistance states are associated
with endothelial dysfunction particularly in the microvas-
culature. Both our group and the Framingham group have
shown a relationship among obesity metrics, metabolic
syndrome, and peripheral microvascular function (4,5).
The distribution of fat appears important because waist
circumference adds to body mass index as a predictor of
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regulated proinﬂammatory gene expression and microvas-
cular endothelial dysfunction, and the degree of adipose
inﬂammation is linked to whole-body insulin resistance and
endothelial dysfunction (7).
Prevention of the obesity pandemic is clearly a high
priority, but what remains troubling is our limited ability to
treat obesity. Lifestyle and dietary interventions have been
well studied but have not been particularly effective. Sus-
tained weight loss is difﬁcult to achieve. Favorable effects on
metabolic parameters including delayed progression to dia-
betes can be achieved. However, the impact of these inter-
ventions on vascular function measurements has been mixed.
More importantly, there are very little data to support that
these interventions alter prognosis. The National Institutes
of Health–sponsored Look AHEAD (Action for Health
in Diabetes) study was recently published. In a cohort of
5,145 patients with obesity and diabetes, intense lifestyle
intervention was able to achieve weight loss of 8.6% at
1 year and 6.0% at study end. When the intervention was
compared with standard care, there was no difference in
cardiovascular outcomes despite some favorable effects on
other parameters (8). These are very sobering results.
In this issue of the Journal, Bigornia et al. (9) examine the
effect of weight loss on vascular function. The study is novel
and important for several reasons: 1) it is much larger than
previous work in this ﬁeld; 2) it evaluates microvascular
function in addition to traditional FMD; 3) it shows
a differential effect based on insulin levels; and 4) it includes
a large cohort of patients undergoing gastric bypass bariatric
surgery. A total of 208 obese patients (32% with diabetes)
underwent lifestyle intervention alone (48%) or a Roux-en-Y
gastric bypass (52%) in a nonrandomized fashion. Vascular
function was assessed at baseline and 1 year. A weight loss of
>10% was achieved in 112 patients (88% of whom had
bariatric surgery), and this weight loss was associated with
favorable changes in most metabolic parameters compared
with those who did not achieve a 10% weight loss. There
was a within-group improvement in microvascular function
(hyperemic ﬂow) but no change in FMD.
The researchers then stratiﬁed the analysis by the median
value of the baseline insulin level (12 mIU/ml) and present
some interesting observations. In patients with insulin
levels below the median value, even a 10% weight loss was
not associated with improvement in either conduit vessel or
microvascular function despite favorable effects on vascular
metabolic risk factors. In those with insulin levels above 12
mIU/ml, baseline microvascular function was attenuated,
and there was a higher burden of risk factors including
diabetes. In this group, a 5% weight loss was associated
with improvements in microvascular function and a 10%
weight loss was associated with improved FMD and
hyperemic ﬂow.
1. 10% weight loss target: The ﬁrst message to take away
from the study is that a 10% weight-loss target
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2307did achieve signiﬁcant metabolic improvement and
normalization of microvascular function. Recent
studies using primarily lifestyle and dietary interven-
tions have achieved weight loss of 5% to 7% and have
not shown a favorable effect on large vessel function
(10). The relative importance of achieving conduit
vessel versus microvascular function improvement has
not been clearly established. It is key to point out that
the majority of patients in the current study achieved
10% weight loss with bariatric surgery. There have
been several small reports of gastric bypass improving
FMD, including previous reports by the current
researchers. However, the current study is the most
convincing and the ﬁrst to evaluate hyperemic ﬂow.
Although the favorable clinical effects of bariatric
surgery are beginning to emerge, the SOS (Swedish
Obese Subjects) study has followed 2,010 patients
who underwent bariatric surgery and a contempora-
neous control group for more than 15 years. They
demonstrated a decrease in all-cause mortality and
cardiovascular events (11). Animal studies have
helped to elucidate mechanisms and have demon-
strated beneﬁcial effects of gastric bypass on measures
of inﬂammation and oxidative stress.
2. Insulin as a biomarker: The second message is more
tantalizing and requires further study. The researchers
stratiﬁed the analysis based on the median insulin
values. One rationale for this was that insulin was an
independent predictor of beneﬁt in the SOS study
(along with age, diabetes, previous vascular disease,
blood pressure, and smoking). In that study, the
median value was 17 mIU/ml (compared with 4 to 6
mIU/ml in healthy controls). Thus, in the current
study, patients in the “low insulin” (<12 mIU/ml)
group still had elevated insulin levels. However, their
vascular responses were not modulated by even a 10%
weight loss and bariatric surgery. Those in the higher
insulin group with 10% weight loss had similar
reductions in lipid parameters that could affect
endothelial function compared with the low insulin
group. However, there was a striking reduction in
insulin levels in this group. Insulin resistance is asso-
ciated with endothelial dysfunction and microvascular
dysfunction via abnormalities in a number of signaling
pathways, attenuation of NO, up-regulation of
inﬂammatory cytokines and free fatty acids, and a state
of oxidative stress. Medical targets of hyper-
insulinemia continue to be developed and have ach-
ieved some success. Metformin ﬁrst-line therapy in
diabetes has been shown to improve vascular function
and attenuate cardiovascular risk. One could speculate
that the dramatic decline in insulin levels in the high
insulin group, achieved mainly with gastric bypass,
led to favorable effects on microvascular and conduit
vessel function. This assumption would need to be
proven but is supported by some animal studies.Obesity and insulin resistance are associated with vascular
dysfunction, particularly in the microvasculature, leading to
enhanced cardiovascular risk. The current study provides
strong support for the potential beneﬁcial effects of >10%
weight loss, which is mainly achieved through bariatric
approaches. Lifestyle, dietary, and exercise approaches to
weight loss remain the cornerstone of risk reduction,
although they have not convincingly led to improvement in
vascular health or decreased number of cardiovascular events.
The importance of hyperinsulinemia as a biomarker of
weight-loss efﬁcacy is suggested by this study and is
hypothesis generating for future work. Whether insulin
levels would be used to decide about the suitability of
a patient for bariatric surgery is unlikely at this point, given
the myriad of beneﬁcial effects on quality of life that this
procedure has. However, this information may help inform
about expected outcomes and plan the next generation of
clinical trials to tackle our growing obesity epidemic.
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